• 1
    Suzuki M. Lymphocyte functions of child patients with ALL (acute lymphoblastic leukemia) in remission. Jpn J Clin Oncol. 1984;14:31-40.
  • 2
    Moritz B, Eder J, Meister B, Heitger A. Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy. Med Pediatr Oncol. 2001;36:283-289.
  • 3
    Kristinsson VH, Kristinsson JR, Jonmundsson GK, Jonsson OG, Thorsson AV, Haraldsson A. Immunoglobulin class and subclass concentrations after treatment of childhood leukemia. Pediatr Hematol Oncol. 2001;18:167-172.
  • 4
    Reinhardt D, Houliara K, Pekrun A, Lakomek M, Krone B. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer. Scand J Infect Dis. 2003;35:851-857.
  • 5
    Alanko S, Salmi TT, Pelliniemi TT. Recovery of natural killer cells after chemotherapy for childhood acute lymphoblastic leukemia and solid tumors. Med Pediatr Oncol. 1995;24:373-378.
  • 6
    Lovat PE, Robinson JH, Windebank KP, Kernahan J, Watson JG. Serial study of T lymphocytes in childhood leukemia during remission. Pediatr Hematol Oncol. 1993;10:129-139.
  • 7
    Fugi S, Kapp M, Einsele H. Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2012;49:10-14.
  • 8
    Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49(RR-10):1-125, CE1-CE7.
  • 9
    Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer. 1992;69:1481-1486.
  • 10
    Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood lymphocytes and serum immunoglobulins after treatment of solid tumors in children. Pediatr Hematol Oncol. 1994;11:33-45.
  • 11
    Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood T-cell subsets after chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol. 1994;11:281-292.
  • 12
    Mazur B, Mertas A, Sonta-Jakimczyk D, Szczepanski T, Janik-Moszant A. Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy. Hematol Oncol. 2004;22:27-34.
  • 13
    Mazur B, Szczepanski T, Karpe J, Sonta-Jakimczyk D, Bubala H, Torbus M. Decreased numbers of CD4+ T lymphocytes in peripheral blood after treatment of childhood acute lymphoblastic leukemia. Leuk Res. 2006;30:33-36.
  • 14
    Eckschlager T, Prusa R, Hladikova M, Radvanska J, Slaby K, Radvansky J. Lymphocyte subpopulations and immunoglobulin levels in Hodgkin's disease survivors. Neoplasma. 2004;51:261-264.
  • 15
    Leung W, Neale G, Behm F, Finkelstein D, Kastan MD, Pui CH. Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia. Cancer Epidemiol. 2010;34:303-308.
  • 16
    Ek T, Mellander L, Hahn-Zoric M, Abrahamsson J. Intensive treatment for childhood acute lymphoblastic leukemia reduces immune responses to diphtheria, tetanus, and Haemophilus influenzae type B. J Pediatr Hematol Oncol. 2004;26:727-734.
  • 17
    Ek T, Mellander L, Andersson B, Abrahamsson J. Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group. Pediatr Blood Cancer. 2005;44:461-468.
  • 18
    Yeh JM, Nekhlyudov L, Goldie S, Mertens AC, Diller L. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med. 2010;152:409-417.
  • 19
    Kurt BA, Nolan VG, Ness KK, et al. Hospitalization rates among survivors of childhood cancer in the Childhood Cancer Survivor Study cohort. Pediatr Blood Cancer. 2012;59:126-132.
  • 20
    Lorenzi MF, Xie L, Rogers PC, Pritchard S, Goddard K, McBride ML. Hospital-related morbidity among childhood cancer survivors in British Columbia, Canada: report of the Childhood, Adolescent, Young Adult Cancer Survivors (CAYACS) Program. Int J Cancer. 2011;128:1624-1631.
  • 21
    Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol. 2002;38:229-239.
  • 22
    Robison LL, Armstrong GT, Boice JD, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009;27:2308-2318.
  • 23
    Leisenring WM, Mertens AC, Armstrong GT, et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2319-2327.
  • 24
    Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
  • 25
    Taylor JM, Munoz A, Bass SM, Saah AJ, Chmiel JS, Kingsley LA. Estimating the distribution of times from HIV seroconversion to AIDS using multiple imputation. Multicentre AIDS Cohort Study. Stat Med. 1990;9:505-514.
  • 26
    Little RJA, Rubin DB. Statistical Analysis With Missing Data. New York; John Willey & Sons, Inc.; 2002.
  • 27
    Gamis AS, Howells WB, DeSwarte-Wallace J, et al. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's Cancer Group study CCG-2891. J Clin Oncol. 2000;18:1845-1855.
  • 28
    Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol. 2001;54:214-218.
  • 29
    Kaplinsky C, Spirer Z. Post-splenectomy antibiotic prophylaxis: unfinished story—to treat or not to treat? Pediatr Blood Cancer. 2006;47:740-741.
  • 30
    Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. BMJ. 1996;312:430-434.
  • 31
    American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366.
  • 32
    The Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers. Version 3.0. Arcadia, CA: Children's Oncology Group; 2008.
  • 33
    Green DM, Kun LE, Matthay KK, et al. Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatr Blood Cancer. 2013;60:1083-1094.
  • 34
    Hudson MM, Neglia JP, Woods WG, et al. Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer. 2012;58:334-343.